Balyasny Asset Management »

Rapport Therapeutics shares owned by Balyasny Asset Management

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Balyasny Asset Management from 13F filings

Historical chart of Balyasny Asset Management investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Balyasny Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Balyasny Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $233k 10k 23.26

More positions owned by Balyasny Asset Management

Ishares Tr Russell 2000 Etf (IWM)
Apple Call Option (AAPL)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Select Sector Spdr Tr Financial (XLF)
Microsoft Corporation Call Option (MSFT)
Amazon Call Option (AMZN)
NVIDIA Corporation Call Option (NVDA)
Ishares Tr Core S&p Mcp Etf (IJH)
Vanguard Index Fds Total Stk Mkt (VTI)
Select Sector Spdr Tr Sbi Cons Discr (XLY)
Mastercard Incorporated Cl A Call Option (MA)
Hess Call Option (HES)
Lockheed Martin Corporation Call Option (LMT)
Endeavor Group Hldgs Cl A Com Put Option (EDR)

View all positions for Balyasny Asset Management

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Capital Research and Management Company - Division 3
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
Alliancebernstein
T. Rowe Price Associates
Perceptive Advisors
BlackRock
Citadel Advisors
Siren
Logos Global Management
Geode Capital Management
Woodline Partners

View all funds holding Rapport Therapeutics